Fig. 1From: The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myelomaTrial flow diagram. *All participants who are eligible and provide informed consent will be randomised. A minimum of 140 participants are requiredBack to article page